AuroMedics Pharma LLC v. Ingenus Pharmaceuticals, LLC
1:20-cv-01235
Overview
Parties
Defendant
Ingenus Pharmaceuticals, LLC Operating Company
Represented By
5 Attorneys ListedSmith, Katzenstein, & Jenkins LLP
1000 West Street, Suite 1501, Wilmington, DE 19801
Smith, Katzenstein & Jenkins, LLP
1000 N. West St., Suite 1501
Smith, Katzenstein, & Jenkins LLP
1000 West Street, Suite 1501, Wilmington, DE 19801
Smith, Katzenstein, & Jenkins LLP
1000 West Street, Suite 1501, Wilmington, DE 19801
Plaintiff
SciDose LLC Operating Company
Represented By
5 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
AuroMedics Pharma LLC Operating Company
Represented By
5 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 3 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 9,662,342 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2017023201 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2014619912 | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9662342
Formulations of cyclophosphamide liquid concentrate
|
Filed: 2015-05-01
Issued: 2017-05-30
|
Active (8.6 yrs remaining)
+56d PTA
Expires: 2035-06-26
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
29
Dispositive
15
Granted
0
Denied
0
Pending / Review
22
Motions by Category
Key Dispositive Motions & Rulings